Back to Search Start Over

Fungal endophthalmitis associated with compounded products.

Authors :
Mikosz CA
Smith RM
Kim M
Tyson C
Lee EH
Adams E
Straif-Bourgeois S
Sowadsky R
Arroyo S
Grant-Greene Y
Duran J
Vasquez Y
Robinson BF
Harris JR
Lockhart SR
Török TJ
Mascola L
Park BJ
Source :
Emerging infectious diseases [Emerg Infect Dis] 2014 Feb; Vol. 20 (2), pp. 248-56.
Publication Year :
2014

Abstract

Fungal endophthalmitis is a rare but serious infection. In March 2012, several cases of probable and laboratory-confirmed fungal endophthalmitis occurring after invasive ocular procedures were reported nationwide. We identified 47 cases in 9 states: 21 patients had been exposed to the intraocular dye Brilliant Blue G (BBG) during retinal surgery, and the other 26 had received an intravitreal injection containing triamcinolone acetonide. Both drugs were produced by Franck's Compounding Lab (Ocala, FL, USA). Fusarium incarnatum-equiseti species complex mold was identified in specimens from BBG-exposed case-patients and an unopened BBG vial. Bipolaris hawaiiensis mold was identified in specimens from triamcinolone-exposed case-patients. Exposure to either product was the only factor associated with case status. Of 40 case-patients for whom data were available, 39 (98%) lost vision. These concurrent outbreaks, associated with 1 compounding pharmacy, resulted in a product recall. Ensuring safety and integrity of compounded medications is critical for preventing further outbreaks associated with compounded products.

Details

Language :
English
ISSN :
1080-6059
Volume :
20
Issue :
2
Database :
MEDLINE
Journal :
Emerging infectious diseases
Publication Type :
Academic Journal
Accession number :
24447640
Full Text :
https://doi.org/10.3201/eid2002.131257